The Marketing Authorisation Application (MAA) has been validated and accepted for full approval consideration with a standard review timeline Additional filings are planned for the U.K., Canada and other regions included in Eisai's licensed territories Taletrectinib is already approved in the U.S., China and Japan for advanced ROS1-positive non-small cell lung cancer TOKYO and NEW YORK, March 26, 2026 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"), a human-cent

Remote camera-based neck rehabilitation platform enables clinician-prescribed sensorimotor home exercises. MINNEAPOLIS, MN, UNITED STATES, March 26, 2026 / EINPresswire.com / -- NeckCare , a medical device company specializing in objective cervical spine assessment and rehabilitation technology, today announced the launch of NeckCare Home™, a remote rehabilitation platform that allows patients to complete clinician-prescribed neck exercises at home using personal devices. Clinicians assign home

Timely resolution of inflammation induced by standard-of-care cancer treatments can be a common approach to prevent cancer recurrence in multiple cancer types We are glad to report the previously unrecognized phenomenon of critical dependence of efficacy of TREM-1 blockade in preventing cancer recurrence on inhibitor specificity and treatment timing” — Alexander B. Sigalov, Ph.D., President and Founder of SignaBlok SHREWSBURY, MA, UNITED STATES, March 26, 2026 / EINPresswire.com / -- SignaBlok,

FDA grants Orphan Drug Designation to SignaBlok's first-in-class, new mechanism-based TREM-1 peptide inhibitor to treat retinopathy of prematurity “Orphan Drug Designation for ROP represents a significant milestone for SignaBlok. Our favorable preclinical data will be presented at the 2026 ARVO conference in Denver, Colorado, May 3-7, 2026".” — Alexander B. Sigalov, Ph.D., President and Founder of SignaBlok SHREWSBURY, MA, UNITED STATES, March 26, 2026 / EINPresswire.com / -- SignaBlok, Inc. , a

Fertility Institute of San Diego Introduces Precision IVF Program Integrating Chloe AI, Continuous Embryo Monitoring, and Undisturbed Culture Providing visual access to embryo development helps patients better understand how their embryos grow and how embryo selection decisions are made.” — Dr. Minoos Hosseinzadeh SAN DIEGO, CA, UNITED STATES, March 26, 2026 / EINPresswire.com / -- Fertility Institute of San Diego today announced the launch of its Precision IVF program , a laboratory approach th

Global initiative to scale advanced therapeutic treatments to accelerate patient access worldwide. TUCSON, Ariz. and AMSTERDAM, March 26, 2026 /PRNewswire/ -- Critical Path Institute® (C-Path) today announced the launch of One to Millions, a global, multi-stakeholder public-private initiative to enable scalable development of advanced therapies for highly individualized conditions. Rapid advances in technologies such as antisense oligonucleotides, genome editing, gene therapies, and RNA-based tr

WASHINGTON, March 26, 2026 /PRNewswire/ -- Today, the Taxpayers Protection Alliance (TPA) released a report, "Blocking Breakthroughs: Delays and Denials at the FDA," highlighting the many issues with the Food and Drug Administration's (FDA's) drug approval process. The report comes amid continued controversy over the agency insisting on unrealistic and ethically-fraught criteria for approvals and walking back a bizarre decision to refuse to examine an application by Moderna for its first mRNA se

SAN ANTONIO, March 26, 2026 /PRNewswire/ -- UT Health San Antonio, the academic health center of The University of Texas at San Antonio (UT San Antonio), has announced a $6.5 million gift from San Antonio philanthropist Harvey E. Najim to establish the Harvey E. Najim Pediatric Health Scholars Program to support future pediatric-focused professionals in dentistry, medicine and nursing in San Antonio and the surrounding region. The Harvey E. Najim Pediatric Health Scholars Program will ease fin

NORTH CHICAGO, Ill., March 26, 2026 /PRNewswire/ -- Rosalind Franklin University announced today that Paige Arneson-Wissink, PhD, assistant professor of biochemistry and molecular biology in the Center for Genetic Diseases, has been awarded a three-year, $747,000 grant from the National Cancer Institute (NCI) to support her research on cachexia in pancreatic ductal adenocarcinoma (PDAC), an aggressive and highly lethal form of cancer. Cachexia, a metabolic disorder that causes the body to break

ALBANY, N.Y. & SHANGHAI--(BUSINESS WIRE)--Drug Farm today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to DF-003, the company’s investigational small molecule inhibitor targeting ALPK1, for the treatment of patients with ROSAH syndrome, a rare, genetically driven systemic autoinflammatory disease with significant unmet medical need. ROSAH syndrome (Retinal dystrophy, Optic nerve edema, Splenomegaly, Anhidrosis, and Headache) is a progressiv